Schizophrenia

Did you know that schizophrenia affects more than 1 percent of the world's population?

See NARSAD Grants at work on the latest schizophrenia research

Schizophrenia is a severe, chronic, and generally disabling brain and behavior disorder. It is most accurately described as a psychosis - a type of illness that causes severe mental disturbances that disrupt normal thoughts, speech, and behavior. Schizophrenia is believed to be caused by a combination of genetic and environmental factors.

Positive symptoms may include delusions, thought disorders, and hallucinations. People with schizophrenia may hear voices other people don't hear, or believe other people are reading their minds, controlling their thoughts, or plotting to harm them. Negative symptoms may include avolition (a lack of desire or motivation to accomplish goals), lack of desire to form social relationships, and blunted affect and emotion. Cognitive symptoms involve problems with attention and memory, especially in planning and organization to achieve a goal. Cognitive deficits are the most disabling for patients trying to lead a normal life.

learn more about schizophrenia

Visit the Schizophrenia Research Forum, fully sponsored by the Brain & Behavior Research Foundation—a virtual community of scientists collaborating in their quest for causes, improved treatments, and better understanding of schizophrenia.

Visit the Schizophrenia Research Forum for more information about research

 

Patrick F. Sullivan, M.D., Professor and Director of Psychiatric Genonomics at the University of North Carolina School of Medicine, Autism, Schizophrenia, Bipolar Disorder
Patrick F. Sullivan, M.D.
July 05, 2012
A new study published online in the Archives of General Psychiatry on July 2 found that a family history of schizophrenia and/or bipolar disorder is a risk...
Marco P. Boks, M.D., Ph.D., Rudolf Magnus Institute of Neuroscience, 2009 NARSAD Young Investigator  Grantee, expert on Bipolar Disorder and Schizophrenia and epigenetics
Marco P. Boks, M.D., Ph.D.
July 03, 2012
Marco P. Boks, M.D., Ph.D., Rudolf Magnus Institute of Neuroscience, 2009 NARSAD Young Investigator Grantee: "Methylation as an Epigenetic Cause of...
Richard Keefe, Ph.D., Director of the Schizophrenia Research Group at the Duke Institute for Brain Sciences, schizophrenia expert
Richard Keefe, Ph.D.
June 28, 2012
Brain & Behavior Research Foundation Scientific Council Member Richard Keefe, Ph.D., Director of the Schizophrenia Research Group at the Duke Institute for...
Scientific Council member Anil K. Malhotra, M.D.,  professor of psychiatry at Hofstra North Shore-LIJ School of Medicine and also serves in the Division of Psychiatry Research in the Zucker Hillside Hospital campus of The Feinstein Institute for Medical Research, both in New York, Expert on mental illness
Anil K. Malhotra, M.D.
June 19, 2012
‘Second’ generation antipsychotic medications are known as atypical antipsychotic drugs (AAPD). Among them are clozapine and olanzapine (Clozaril® and Zyprexa...
Janet Susin, president of the Queens/Nassau chapter of the National Alliance on Mental Illness
Janet Susin
June 08, 2012
A Leader at NAMI Discusses Her Unwavering 25-Year Support of the Brain & Behavior Research Foundation Like many donors to the Brain & Behavior Research...

Pages

Subscribe to